HMPAO SPECT brain imaging in treatment-resistant depression

Prog Neuropsychopharmacol Biol Psychiatry. 1997 Oct;21(7):1097-114. doi: 10.1016/s0278-5846(97)00100-0.

Abstract

1. There is little published research on brain function in treatment-resistant depression (TRD). This study examined regional cerebral blood flow using 99mTechnetium-hexamethylpropanolamine oxime (HMPAO) single photon emission computed tomography in 8 patients with a history of TRD, 13 depressed patients without TRD (non-TRD) and 16 normal controls. 2. Relative HMPAO activity in selected brain regions revealed a significant increase in hippocampus-amygdala activity in TRD patients compared to non-TRD patients and healthy controls. The mean value of relative HMPAO activity did not differ in any other brain region, nor were there any differences in right-left symmetry among the subject groups. 3. The observation of increased hippocampus-amygdala HMPAO activity in TRD patients suggests that functional abnormalities in limbic circuitry may play a role in the pathophysiology of treatment-resistance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Amygdala / blood supply
  • Antidepressive Agents / therapeutic use
  • Brain / diagnostic imaging*
  • Depressive Disorder / diagnostic imaging*
  • Depressive Disorder / physiopathology
  • Female
  • Functional Laterality
  • Hippocampus / blood supply
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Regional Blood Flow
  • Technetium Tc 99m Exametazime*
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Antidepressive Agents
  • Technetium Tc 99m Exametazime